AAV Capsid Peptide Sequences for Brain Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy vectors, such as wild-type AAV vectors, lack specificity for targeting the brain and spinal cord, leading to inefficient transduction and severe immune reactions due to non-specific tissue infection, and existing methods to enhance specificity are not effective in vivo.
Innovation Solution
Development of viral vectors with novel amino acid sequences specifically recognized by brain and spinal cord neurons and endothelial cells, allowing for systemic administration and targeted transduction of these tissues, using peptides like NRGTEWD, ADGVQWT, DDGVSWK, SDGLTWS, and SDGLAWV, which are integrated into the capsid protein of AAV vectors to enhance tropism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If wild-type AAV vectors are used for systemic administration, then the vectors can be administered systemically, but the vectors infect a wide variety of cell types leading to insufficient target tissue transduction and severe immune reactions
Solution Approach 1:
The patent modifies the capsid protein of AAV vectors by incorporating specific peptide sequences (such as NRGTEWD, ADGVQWT, DDGVSWK, SDGLTWS, and SDGLAWV) that are recognized by receptors on brain and spinal cord cells. This creates local specificity on the capsid surface, enabling the vector to selectively bind to and transduce target tissues in the central nervous system while maintaining systemic administration capability.
2Ease of operation
If wild-type AAV vectors are used for systemic administration, then the vectors can be administered systemically, but severe immune reactions occur due to undesired transduction of other tissues
Solution Approach 1:
By engineering the capsid with tissue-specific peptide sequences, the patent directs the vector exclusively to brain and spinal cord tissues. This localized targeting prevents transduction of non-target tissues, thereby eliminating the source of immune reactions while preserving the ability to administer the vector systemically.
3Ease of operation
If the blood brain barrier is made permeable by ultrasound or chemical agents to allow vector entry, then the barrier becomes permeable for short time, but the method is associated with very high risk for the patient
Solution Approach 1:
The patent uses peptide sequences on the capsid surface as intermediaries that specifically recognize and bind to receptors on brain and spinal cord cells. This mediator approach allows the vector to cross the blood-brain barrier through receptor-mediated mechanisms without requiring physical disruption or chemical agents, thereby eliminating the associated risks.
4Measurement precision
If capsids are selected from randomized peptide libraries to achieve specific transduction, then specific transduction can be achieved in vitro, but the required specificity is missing in an animal model
Solution Approach 1:
The patent identifies and incorporates specific peptide sequences (NRGTEWD, ADGVQWT, DDGVSWK, SDGLTWS, SDGLAWV) that have been validated to maintain their binding specificity from in vitro to in vivo conditions. These parameter-optimized peptides ensure consistent target recognition and specific transduction across different biological environments, resolving the discrepancy between in vitro and in vivo performance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vectors achieve strong and long-lasting transgene expression in brain and spinal cord tissues with minimal immune response, enabling effective gene therapy for neurological diseases by specifically binding to target cells, thereby improving treatment efficacy and safety.
Implementation Method 1
peptides like NRGTEWD, ADGVQWT, DDGVSWK, SDGLTWS, and SDGLAWV, which are integrated into the capsid protein of AAV vectors to enhance tropism
Data Source
AI summary
The invention relates to peptides, polypeptides or proteins which specifically bind to cells of the brain and/or the spinal cord. The peptides, polypeptides or proteins can be part of a viral capsid, and they can be used for guiding a recombinant viral vector selectively to the brain and/or spinal cord after systemic administration to a subject, where it provides for a tissue-specific expression of one or more transgenes. The invention therefore also relates to a recombinant viral vector, preferably an AAV vector, comprising a capsid containing at least one of the peptides, polypeptides or proteins of the invention and at least one transgene which is packaged within the capsid. The viral vector is particularly suitable for the therapeutic treatment of a disease or functional disorder of the brain and/or the spinal cord. The invention further relates to cells and pharmaceutical compositions comprising the viral vector of the invention.